CASIMERSEN - Generic Drug Details

What are the generic drug sources for casimersen and what is the scope of freedom to operate?

Casimersen is the generic ingredient in one branded drug marketed by Sarepta Theraps Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Casimersen has eighty-eight patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for CASIMERSEN

International Patents:	88
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CASIMERSEN
What excipients (inactive ingredients) are in CASIMERSEN?	CASIMERSEN excipients list
DailyMed Link:	CASIMERSEN at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CASIMERSEN

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CASIMERSEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sarepta Therapeutics, Inc.	Phase 2
Kevin Flanigan	Phase 2
Sarepta Therapeutics	Phase 3

See all CASIMERSEN clinical trials

Pharmacology for CASIMERSEN

Drug Class	Antisense Oligonucleotide
Physiological Effect	Increased Protein Synthesis

Anatomical Therapeutic Chemical (ATC) Classes for CASIMERSEN

M09AX	Other drugs for disorders of the musculo-skeletal system
M09A	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M09	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM
M	Musculo-skeletal system

US Patents and Regulatory Information for CASIMERSEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021		RX	Yes	Yes			Y	Y

Expired US Patents for CASIMERSEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021
Sarepta Theraps Inc	AMONDYS 45	casimersen	SOLUTION;INTRAVENOUS	213026-001	Feb 25, 2021

International Patents for CASIMERSEN

Country	Patent Number	Title	Estimated Expiration
South Korea	102113306
South Korea	102366851
Israel	314343
South Korea	102581868

CASIMERSEN Market Analysis and Financial Projection

Last updated: April 24, 2026

CASIMERSEN: Market dynamics and financial trajectory

Casimersen (brand: Amondys 45) is an antisense oligonucleotide (AON) indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation in the dystrophin gene that is amenable to exon 45 skipping. The commercial and financial trajectory is shaped by three forces: (1) the addressable exon-45 mutation pool, (2) payer coverage and high net pricing typical for AONs, and (3) competitive displacement versus other exon-skipping therapies where clinical positioning overlaps.

What governs the addressable market for casimersen?

Casimersen’s market is limited by two filters: mutation amenability (exon 45 skipping) and diagnostic behavior (how quickly and broadly DMD patients receive genetic testing and are matched to exon skipping options).

Market gate	Mechanism	Impact on demand
Mutation amenability	Only patients with exon 45 amenable mutations qualify	Narrows the pool relative to DMD programs with broader exon coverage
Treatment decision	Physicians and payers align therapy choice to genotype and real-world eligibility	Slows adoption when testing rates are uneven
Competitive overlap	Other exon-skipping AONs compete within genotype-defined segments	Shifts share inside the exon-skipping submarket

How has the product scaled commercially in the real market?

Public commercial trajectory is observable through the pattern of U.S. uptake for Amondys 45 since launch, with later-stage competitive pressure from other exon-skipping options and by broader shifts in DMD treatment selection.

Launch-era dynamics and early adoption

• Approval pathway created initial market access via labeling tied to “confirmed mutation … amenable to exon 45 skipping,” enabling genetic-test-driven prescribing once payers accepted genotype documentation.
• Early uptake typically depends on (a) center expertise in AON logistics, (b) access to confirmatory testing, and (c) payer readiness to cover long-term, chronic therapy.

Mid-cycle dynamics: payer tightening and competitive substitution

• As exon-skipping options expanded, payers increasingly used coverage criteria tied to genotype documentation, age/ambulatory criteria (where applicable), and adherence to labeling. That tends to cap growth if subgroups fall outside strict criteria.
• Competitive substitution occurs when patients who are eligible for multiple exon-skipping strategies are rare, but in practice “eligible” is genotype-specific. The more relevant issue is share-of-eligible across mutation segments and center prescribing preferences.

What pricing and reimbursement structure drives financial outcomes?

The AON pricing stack matters more than volume once you model DMD chronic treatment economics. Casimersen is priced at a level typical of specialty gene-modifying and AON therapies, with net pricing driven by rebate structures, contracting, and payer mix.

Pricing baseline and commercial expectations

• Amondys 45 is a high-cost chronic infusion therapy, consistent with the broader AON segment pricing model.
• Net sales are determined by: 1) gross-to-net (rebates, discounts, contracts), 2) utilization (eligible patient counts, dosing persistence), 3) channel mix (government vs commercial, specialty pharmacy vs buy-and-bill patterns by payer).

Financial implication

• Because dosing is chronic, sales decline risk is tied more to persistence and coverage changes than to short-term demand swings.
• For AONs, payer actions can appear as:
  • more stringent coverage documentation,
  • prior authorization tightening,
  • step edits in formularies,
  • reclassification to higher tiers or restricted access programs.

What does the competitive landscape do to casimersen’s share?

The DMD exon-skipping market is structured as a set of genotype-defined therapies. Casimersen competes indirectly through:

• portfolio breadth: other exons cover different mutation distributions;
• treatment selection: clinicians and specialty pharmacies manage multiple AONs and choose based on genotype testing turnaround and logistics;
• payer contracting: payers can negotiate in portfolios and apply restrictions across the class.

Competitive set (exon-skipping adjacent)

Key competing AONs in DMD include:

• Eteplirsen (exon 51 skipping)
• Golodirsen (exon 53 skipping)
• Viltolarsen (exon 53 skipping)
• Duvyzat (givinostat) is not exon skipping, but can influence treatment selection in broader disease management.

Casimersen’s share risk is not that it competes for the same genotype. It is that payer and center coverage strategies evolve across the exon-skipping portfolio and that total DMD budgets constrain uptake across multiple expensive therapies.

How do regulatory and evidence cycles translate into financial trajectory?

Financial performance for specialty DMD therapies is strongly correlated with:

• label breadth clarity (does it expand or get narrowed?),
• evidence acceptance (clinical endpoint credibility and real-world durability),
• and post-marketing scrutiny (confirmatory data, safety monitoring, and payer confidence).

Evidence and label anchoring

Casimersen’s label ties use to exon 45 amenable mutations and positions it within the standard DMD exon-skipping framework. That anchoring supports ongoing payer coverage, provided genetic testing documentation is consistently provided.

What are the measurable market dynamics since launch?

The market dynamics show a typical AON pattern:

• initial uptake tied to genotype testing volume and payer onboarding,
• plateau risk when the addressable pool becomes fully identified or when payers tighten criteria,
• share shifts as more exon-skipping options get established and contracting evolves.

Core demand drivers and friction points

Driver	What it changes	Direction of impact
Genetic testing availability	Determines how quickly patients can be matched to exon skipping	Positive for uptake
Payer prior authorization rigor	Affects whether eligible patients actually start	Negative for conversion
Treatment persistence	Drives chronic utilization and refill cadence	Positive for revenue durability
Portfolio competition	Influences contracting and center prescribing patterns	Mix-dependent

Financial trajectory: what the revenue path implies for investors and operators

Casimersen’s financial trajectory is best understood through three metrics investors focus on in specialty AONs: 1) Patient count (eligible pool reached and maintained), 2) Net price (rebates and contracting), 3) Persistence (ongoing infusions and continuity of coverage).

In the AON segment, gross-to-net dynamics typically dominate early and mid-cycle as share grows and contracting matures. Later, persistence and payer durability become the primary levers.

Trajectory profile for casimersen

• Growth phase: conversion from diagnosed and genotyped patients into covered and treated patients.
• Maturation: steady-state patient churn and persistence, with growth limited by the remaining undiagnosed pool.
• Late-cycle pressure: portfolio contracting, potential restriction actions, and competitive channel effects.

This structure yields a financial profile that tends to show:

• early ramp driven by adoption,
• then a plateau shaped by eligible pool depth and payer policy stability,
• with upside coming from expanded diagnostic identification and reduced friction for prior authorization.

Where are the most important swing factors for near-to-mid-term revenues?

1) Rate of genotype identification for exon 45 amenable mutations 2) Payer policy stability for AON coverage criteria 3) Contracting outcome that sets net pricing 4) Specialty channel execution that improves treatment persistence

Revenue sensitivity logic

Because casimersen is chronic, the highest sensitivity to revenue occurs where it alters either:

• treated patient numbers (incidence of covered eligibility), or
• continuation (persistence and refill cadence).

Key market and financial takeaways

• Casimersen’s addressable market is genetically constrained to exon 45 amenable DMD mutations and grows only as diagnosis and matching improve.
• Financial trajectory is primarily driven by net pricing (gross-to-net) and persistence rather than one-time uptake.
• Competitive pressure is portfolio-level and payer-contracting driven, not direct substitution within the same genotype segment.
• The most material swing factors are genotype testing throughput, prior authorization friction, and net contract terms.

---

FAQs

1) What is casimersen’s labeled indication?
Casimersen (Amondys 45) is indicated for the treatment of DMD in patients with a confirmed mutation in the dystrophin gene that is amenable to exon 45 skipping.

2) Is casimersen a “one-off” treatment or chronic?
It is a chronic therapy administered by repeated infusions, which makes persistence a major driver of revenue.

3) What limits the size of the casimersen market?
The market is constrained by the share of DMD patients with exon 45 amenable mutations and the speed at which patients receive genetic testing and are matched to therapy.

4) How does payer behavior influence revenue?
Payer prior authorization and coverage criteria influence conversion from eligible to treated patients, while contracting drives net pricing and can cap growth even when demand exists.

5) How does competition affect casimersen?
Competition affects casimersen through DMD exon-skipping portfolio contracting and center prescribing behavior, which can shift share across genotype-defined segments and influence access.

---

References

[1] FDA. (2020). Amondys 45 (casimersen) prescribing information. U.S. Food and Drug Administration.